结论国产与进口雷帕霉素支架治疗分叉病变患者的早中期疗效相似。
Conclusion Short-term and middle-term outcomes of treating bifurcation lesions with domestic and imported sirolimus-eluting stent techniques in patients is similar.
目的：探讨ST段抬高性心肌梗死患者经皮冠状动脉介入置入雷帕霉素药物洗脱支架内血栓形成的相关因素及预后。
Objective to study the related factors and prognosis of rapamycin drug-eluting stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
方法64例冠状动脉分叉病变患者随机分为两组，分别植入雷帕霉素涂层支架及普通支架，每组32例。
Methods 64 patients with bifurcation coronary artery lesion were randomly divided into rapamycin stent group and ordinary stent group, 32 cases in each group.
目的评价雷帕霉素涂层支架在冠状动脉分叉病变中的临床疗效。
Objective To evaluate the clinic effect of CYPHERTM (rapamycin) stent in treatment of bifurcation coronary artery lesion.
结论雷帕霉素洗脱支架术治疗多支冠状动脉病变患者长期疗效与CABG相当，是治疗多支病变冠心病患者一种较好的方法。
Conclusion a better treatment for the patients with multi-vessel coronary disease, rapamycin-eluting stent implantation has the clinical effects comparable to those of the CABG.
目的比较雷帕霉素洗脱支架术与冠状动脉旁路移植术(CABG)治疗多支冠状动脉病变的临床疗效。
Objective To compare the clinical effects of rapamycin-eluting stent implantation and coronary artery bypass grafting (CABG) in treatment of the patients with multi-vessel coronary disease.
本文就目前雷帕霉素涂层支架在临床防治再狭窄研究的最新进展作一综述。
The purpose of this article is to review the relevant preclinical and clinical data in the field of rapamycin eluting stent for the prevention of restenosis.
雷帕霉素即制药商惠氏（Wyeth）的品牌免疫抑制剂雷帕鸣（Rapamune），它常用来阻碍器官移植和心脏支架手术后的排斥反应。
The compound is branded by drug maker Wyeth as Rapamune and is used to suppress the immune system and ward off rejection after organ transplants and in heart stents.
雷帕霉素即制药商惠氏（Wyeth）的品牌免疫抑制剂雷帕鸣（Rapamune），它常用来阻碍器官移植和心脏支架手术后的排斥反应。
The compound is branded by drug maker Wyeth as Rapamune and is used to suppress the immune system and ward off rejection after organ transplants and in heart stents.
应用推荐